Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 945-954

  Buettner, Ralf ^a   Mora, Linda B ^a   Jove, Richard ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN D2; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; INHIBITOR OF APOPTOSIS PROTEIN; JANUS KINASE; MYC PROTEIN; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

APOPTOSIS; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; GENE ACTIVATION; GENE ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; DNA, ANTISENSE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0036554816     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (113)

1. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Wash. DC), 264: 1415-1421, 1994.
2. Bromberg, J., and Darnell, J. E., Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19: 2468-2473, 2000.
3. Darnell, J. E., Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J. Interferon Cytokine Res., 18: 549-554, 1998.
4. Decker, T., and Kovarik, P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell. Mol. Life Sci, 55: 1535-1546, 1999.
5. Schindler, C., and Brutsaert, S. Interferons as a paradigm for cytokine signal transduction. Cell. Mol. Life Sci., 55: 1509-1522, 1999.
6. Darnell, J. E., Jr. STATs and gene regulation. Science (Wash. DC), 277: 1630-1635, 1997.
7. Wurster, A. L., Tanaka, T., and Grusby, M. J. The biology of Stat4 and Stat6. Oncogene, 19: 2577-2584, 2000.
8. Akira, S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene, 19: 2607-2611, 2000.
9. Levy, D. E. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell. Mol. Life Sci., 55: 1559-1567, 1999.
10. Ihle, J. N. Cytokine receptor signaling. Nature (Lond.), 377: 591-594, 1995.
11. Ramana, C. V., Chatterjee-Kishore, M., Nguyen, H., and Stark, G. R. Complex roles of Stat1 in regulating gene expression. Oncogene, 19: 2619-2627, 2000.
12. Kotenko, S. V., and Pestka, S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene, 19: 2557-2565, 2000.
13. Dearolf, C. R. JAKs and STATs in invertebrate model systems. Cell. Mol. Life Sci., 55: 1578-1584, 1999.
14. Lin, J. X., and Leonard, W. J. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene, 19: 2566-2576, 2000.
15. Schindler, C., and Darnell, J. E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem., 64: 621-651, 1995.
16. Zeidler, M. P., Bach, E. A., and Perrimon, N. The roles of the Drosophila Jak/Stat pathway. Oncogene, 19: 2598-2606, 2000.
17. Hirano, T., Ishihara, K., and Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation, and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 19: 2548-2556, 2000.
18. Smithgall, T. E., Briggs, S. D., Schreiner, S., Lerner, E. C., Cheng, H., and Wilson, M. B. Control of myeloid differentiation and survival by Stats. Oncogene, 19: 2612-2618, 2000.
19. Mui, A. L. The role of STATs in proliferation, differentiation, and apoptosis. Cell. Mol. Life Sci., 55: 1547-1558, 1999.
20. Ihle, J. N. The Stat family in cytokine signaling. Curr. Opin. Cell Biol., 13: 211-217, 2001.
21. Herrington, J., Smit, L. S., Schwartz, J., and Carter-Su, C. The role of STAT proteins in growth hormone signaling. Oncogene, 19: 2585-2597, 2000.
22. Reddy, E. P., Korapati, A., Chaturvedi, P., and Rane, S. IL-3 signaling and the role of Src kinases. JAKs and STATs: a covert liaison unveiled. Oncogene, 19: 2532-2547, 2000.
23. Turkson, J., and Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19: 6613-6626, 2000.
24. Garcia, R., and Jove, R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci., 5: 79-85, 1998.
25. Catlett-Falcone, R., Dalton, W. S., and Jove, R. STAT proteins as novel targets for cancer therapy. Signal transducer and activator of transcription. Curr. Opin. Oncol., 11: 490-496, 1999.
26. Bowman, T., Garcia, R., Turkson, J., and Jove, R. STATs in oncogenesis. Oncogene, 19: 2474-2488, 2000.
27. Song, J. I., and Grandis, J. R. STAT signaling in head and neck cancer. Oncogene, 19: 2489-2495, 2000.
28. Coffer, P. J., Koenderman, L., and de Groot, R. P. The role of STATs in myeloid differentiation and leukemia. Oncogene, 19: 2511-2522, 2000.
29. Lin, T. S., Mahajan, S., and Frank, D. A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene, 19: 2496-2504, 2000.
30. Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A., and Jove, R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 20: 2499-2513, 2001.
31. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999.
32. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., and Darnell, J. E., Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl. Acad. Sci. USA, 93: 7673-7678, 1996.
33. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., and Schreiber, R. D. Targeted disruption of the Statl gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84: 431-442, 1996.
34. Durbin, J. E., Hackenmiller, R., Simon, M. C., and Levy, D. E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell, 84: 443-450, 1996.
35. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., and Schreiber, R. D. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA, 95: 7556-7561, 1998.
36. Levy, D. E., and Gilliland, D. G. Divergent roles of Stat1 and Stat5 in malignancy as revealed by gene disruptions in mice. Oncogene, 19: 2505-2510, 2000.
37. Sahni, M., Ambrosetti, D. C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev., 13: 1361-1366, 1999.
38. Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., and Tweardy, D. J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Investig., 102: 1385-1392, 1998.
39. Ramana, C. V., Grammatikakis, N., Chernov, M., Nguyen, H., Goh, K. C., Williams, B. R., and Stark, G. R. Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways. EMBO J., 19: 263-272, 2000.
40. Donato, N. J., Wu, J. Y., Zhang, L., Kantarjian, H., and Talpaz, M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood, 97: 2846-2853, 2001.
41. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., and Loughran, T. P., Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Investig., 107: 351-362, 2001.
42. Heim, M. H., Kerr, I. M., Stark, G. R., and Darnell, J. E., Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science (Wash. DC), 267: 1347-1349, 1995.
43. Danial, N. N., and Rothman, P., Jak-Stat signaling activated by Abl oncogenes. Oncogene, 19: 2523-2531, 2000.
44. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., Jr., and Kuriyan, J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell, 93: 827-839, 1998.
45. Haspel, R. L., and Darnell, J. E., Jr. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. Proc. Natl. Acad. Sci. USA, 96: 10188-10193, 1999.
46. Becker, S., Groner, B., and Muller, C. W. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature (Lond.), 394: 145-151, 1998.
47. Vinkemeier, U., Cohen, S. L., Moarefi, I., Chait, B. T., Kuriyan, J., and Darnell, J. E., Jr. DNA binding of in vitro activated Stat1 α, Stat1 β and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J., 15: 5616-5626, 1996.
48. John, S., Vinkemeier, U., Soldaini, E., Darnell, J. E., Jr., and Leonard, W. J. The significance of tetramerization in promoter recruitment by Stat5. Mol. Cell. Biol., 19: 1910-1918, 1999.
49. Shuai, K., Horvath, C. M., Huang, L. H., Qureshi, S. A., Cowburn, D., and Darnell, J. E., Jr. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 76: 821-828, 1994.
50. Wen, Z., Zhong, Z., and Darnell, J. E., Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 82: 241-250, 1995.
51. Caldenhoven, E., van Dijk, T. B., Solari, R., Armstrong, J., Raaijmakers, J. A., Lammers, J. W., Koenderman, L., and de Groot, R. P. STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem., 271: 13221-13227, 1996.
52. Sasse, J., Hemmann, U., Schwartz, C., Schniertshauer, U., Heesel, B., Landgraf, C., Schneider-Mergener, J., Heinrich, P. C., and Horn, F. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol. Cell. Biol., 17: 4677-4686, 1997.
53. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. Stat3 as an oncogene. Cell, 98: 295-303, 1999.
54. Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., and Akira, S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA, 94: 3801-3804, 1997.
55. Chapman, R. S., Lourenco, P. C., Tonner, E., Flint, D. J., Selbert, S., Takeda, K., Akira, S., Clarke, A. R., and Watson, C. J. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev., 13: 2604-2616, 1999.
56. Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., Yoshikawa, K., Akira, S., and Takeda, J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J., 18: 4657-4668, 1999.
57. Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., and Akira, S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity, 10: 39-49, 1999.
58. Garcia, R., Yu, C. L., Hudnall, A., Catlett, R., Nelson, K. L., Smithgall, T., Fujita, D. J., Ethier, S. P., and Jove, R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ., 8: 1267-1276, 1997.
59. Yu, C. L., Meyer, D. J., Campbell, G. S., Lamer, A. C., Carter-Su, C., Schwartz, J., and Jove, R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (Wash. DC), 269: 81-83, 1995.
60. Cao, X., Tay, A., Guy, G. R., and Tan, Y. H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol., 16: 1595-1603, 1996.
61. Chaturvedi, P., Sharma, S., and Reddy, E. P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol., 17: 3295-3304, 1997.
62. Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., and Darnell, J. E., Jr. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol., 18: 2553-2558, 1998.
63. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., and Jove, R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol., 18: 2545-2552, 1998.
64. Chiu, J. J., Sgagias, M. K., and Cowan, K. H. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res., 2: 215-221, 1996.
65. Copeland, N. G., Gilbert, D. J., Schindler, C., Zhong, Z., Wen, Z., Darnell, J. E., Jr., Mui, A. L., Miyajima, A., Quelle, F. W., and Ihle, J. N. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics, 29: 225-228, 1995.
66. Park, S. H., Liu, X., Hennighausen, L., Davey, H. W., and Waxman, D. J. Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J. Biol. Chem., 274: 7421-7430, 1999.
67. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G., and Ihle, J. N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell, 93: 841-850, 1998.
68. Socolovsky, M., Fallon, A. E., Wang, S., Brugnara, C., and Lodish, H. F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell, 98: 181-191, 1999.
69. Wakao, H., Gouilleux, F., and Groner, B. Mammary gland factor (MGF) is a novel member of the cytokine-regulated transcription factor gene family and confers the prolactin response. EMBO J., 13: 2182-2191, 1994.
70. Liu, X., Robinson, G. W., Wagner, K. U., Garrett, L., Wynshaw-Boris, A., and Hennighausen, L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev., 11: 179-186, 1997.
71. Moriggl, R., Sexl, V., Piekorz, R., Topham, D., and Ihle, J. N. Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity, 11: 225-230, 1999.
72. Moriggl, R., Topham, D. J., Teglund, S., Sexl, V., McKay, C., Wang, D., Hoffmeyer, A., van Deursen, J., Sangster, M. Y., Bunting, K. D., Grosveld, G. C., and Ihle, J. N. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity, 10: 249-259, 1999.
73. Onishi, M., Nosaka, T., Misawa, K., Mui, A. L., Gorman, D., McMahon, M., Miyajima, A., and Kitamura, T. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol., 18: 3871-3879, 1998.
74. Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., and Sawyers, C. L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene, 13: 247-254, 1996.
75. Mes-Masson, A. M., McLaughlin, J., Daley, G. Q., Paskind, M., and Witte, O. N. Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA, 83: 9768-9772, 1986.
76. Pendergast, A. M., Muller, A. J., Havlik, M. H., Maru, Y., and Witte, O. N. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a nonphosphotyrosine-dependent manner. Cell, 66: 161-171, 1991.
77. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (Wash. DC), 247: 1079-1082, 1990.
78. Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M., and Griffin, J. D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood, 95: 2118-2125, 2000.
79. de Groot, R. P., Raaijmakers, J. A., Lammers, J. W., Jove, R., and Koenderman, L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood, 94: 1108-1112, 1999.
80. Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., and Skorski, T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med., 189: 1229-1242, 1999.
81. Danial, N. N., Pernis, A., and Rothman, P. B. Jak-Stat signaling induced by the v-Abl oncogene. Science (Wash. DC), 269: 1875-1877, 1995.
82. Migone, T. S., Lin, J. X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., and Leonard, W. J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (Wash. DC), 269: 79-81, 1995.
83. Demoulin, J. B., Uyttenhove, C., Lejeune, D., Mui, A., Groner, B., and Renauld, J. C. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res., 60: 3971-3977, 2000.
84. Grandis, J. R., Drenning, S. D., Zeng, Q., Watkins, S. C., Melhem, M. F., Endo, S., Johnson, D. E., Huang, L., He, Y., and Kim, J. D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA, 97: 4227-4232, 2000.
85. Gesbert, F., and Griffin, J. D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood, 96: 2269-2276, 2000.
86. Karni, R., Jove, R., and Levitzki, A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene, 18: 4654-4662, 1999.
87. Zhou, P., Qian, L., Kozopas, K. M., and Craig, R. W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood, 89: 630-643, 1997.
88. Epling-Burnette, P. K., Zhong, B., Bai, F., Jiang, K., Bailey, R. D., Garcia, R., Jove, R., Djeu, J. Y., Loughran, T. P., Jr., and Wei, S. Cooperative regulation of Mcl-1 by Janus kinase/Stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J. Immunol., 166: 7486-7495, 2001.
89. Lord, J. D., McIntosh, B. C., Greenberg, P. D., and Nelson, B. H. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the transactivation domain of Stat5. J. Immunol., 164: 2533-2541, 2000.
90. Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., and Jove, R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA, 98: 7319-7324, 2001.
91. Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., and Jove, R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene, 19: 5419-5427, 2000.
92. Martino, A., Holmes, J. H., IV, Lord, J. D., Moon, J. J., and Nelson, B. H. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J. Immunol., 166: 1723-1729, 2001.
93. Shuai, K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene, 19: 2638-2644, 2000.
94. Greenhalgh, C. J., and Hilton, D. J. Negative regulation of cytokine signaling. J. Leukocyte Biol., 70: 348-356, 2001.
95. Starr, R., and Hilton, D. J. Negative regulation of the JAK/STAT pathway. Bioessays, 21: 47-52, 1999.
96. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., and Yoshimura, A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J., 18: 1309-1320, 1999.
97. Marine, J. C., McKay, C., Wang, D., Topham, D. J., Parganas, E., Nakajima, H., Pendeville, H., Yasukawa, H., Sasaki, A., Yoshimura, A., and Ihle, J. N. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell, 98: 617-627, 1999.
98. Frantsve, J., Schwaller, J., Sternberg, D. W., Kutok, J., and Gilliland, D. G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol., 21: 3547-3557, 2001.
99. Koyama, M., Nagai, H., Bando, K., Ito, M., Moriyama, Y., and Emi, M. Localization of a target region of allelic loss to a 1-cM interval on chromosome 16p.13.13 in hepatocellular carcinoma. Jpn. J. Cancer Res., 90: 951-956, 1999.
100. Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., and Shuai, K. Specific inhibition of Stat3 signal transduction by PIAS3. Science (Wash. DC), 278: 1803-1805, 1997.
101. Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D., and Shuai, K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. USA, 95: 10626-10631, 1998.
102. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. A signature motif in transcriptional coactivators mediates binding to nuclear receptors. Nature (Lond.), 387: 733-736, 1997.
103. Liao, J., Fu, Y., and Shuai, K. Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. Proc. Natl. Acad. Sci. USA, 97: 5267-5272, 2000.
104. Wang, L. H., Yang, X. Y., Mihalic, K., Xiao, W., Li, D., and Farrar, W. L. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by coregulator PIAS3. J. Biol. Chem., 276: 31839-31844, 2001.
105. Janne, O. A., Moilanen, A. M., Poukka, H., Rouleau, N., Karvonen, U., Kotaja, N., Hakli, M., and Palvimo, J. J. Androgen-receptor-interacting nuclear proteins. Biochem. Soc. Trans., 28: 401-405, 2000.
106. Decker, T., and Kovarik, P. Serine phosphorylation of STATs. Oncogene, 19: 2628-2637, 2000.
107. Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J., Sekharam, M., Frank, D. A., Holzman, L. B., Wu, J., Sebti, S., and Jove, R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell. Biol., 19: 7519-7528, 1999.
108. Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research. Science (Wash. DC), 287: 1969-1973, 2000.
109. Niu, G., Heller, R., Catlett-Falcone, R., Coppola, D., Jaroszeski, M., Dalton, W., Jove, R., and Yu, H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res., 59: 5059-5063, 1999.
110. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther., 82: 231-239, 1999.
111. Niu, G., Shain, K. H., Huang, M., Ravi, R., Bedi, A., Dalton, W. S., Jove, R., and Yu, H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res., 61: 3276-3280, 2001.
112. Seidel, H. M., Lamb, P., and Rosen, J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene, 19: 2645-2656, 2000.
113. Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., and Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation, and cell transformation. J. Biol. Chem., 276: 45443-45455, 2001.